Moleculin to Present at 38th Annual ROTH Conference

Rhea-AI Summary

Moleculin (Nasdaq: MBRX) will present at the 38th Annual ROTH Conference in Dana Point, CA, participating in a fireside chat on March 24, 2026, 12:00–12:25 PM PT.

Presenters include Walter Klemp, Founder, President, Chairman & CEO, and Jon Foster, EVP & CFO. Investors may register or arrange one-on-one meetings through ROTH.

Key Figures

Conference edition: 38th Annual Conference dates: March 22–24, 2026 Fireside chat time: 12:00–12:25 PM PT +5 more

8 metrics

Conference edition 38th Annual ROTH Conference series

Conference dates March 22–24, 2026 ROTH Conference schedule

Fireside chat time 12:00–12:25 PM PT MBRX session slot on March 24, 2026

Presentation location Suite 1051 BROWN - HEALTHCARE - VIRTUAL track

Current price $2.05 Before conference participation announcement

52-week range $1.79–$33.00 Low to high prior to this news

Shelf warrant shares 64,864,864 shares Inducement Warrant Shares under S-3 filed 2025-09-19

Potential shelf proceeds $35.7 million Gross proceeds if all shelf-registered warrants exercised for cash

Market Reality Check

Price: $2.16 Vol: Volume 100,050 is 0.34x t...

low vol

$2.16 Last Close

Volume Volume 100,050 is 0.34x the 20-day average of 293,854, indicating subdued trading ahead of the conference. low

Technical Shares at $2.05 are trading below the 200-day MA of $9.8 and far under the $33 52-week high.

Peers on Argus

MBRX gained 0.49% while peers were mixed: LPTX up 238.84%, KZIA up 6.79%, and IN...

MBRX gained 0.49% while peers were mixed: LPTX up 238.84%, KZIA up 6.79%, and INTS/MBIO/SNGX down modestly. No clear sector-wide trend tied to this conference notice.

Historical Context

5 past events · Latest: Mar 11 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 11	CEO Corner update	Positive	+3.0%	CEO discussed MIRACLE Phase 3 progress and upcoming interim unblinding.
Feb 19	Warrant exercise financing	Negative	-44.3%	Immediate warrant exercises for cash and issuance of new warrants drove dilution concerns.
Feb 18	Clinical data update	Positive	+5.5%	Reported 40% blinded CRc in MIRACLE trial with continued absence of cardiotoxicity.
Feb 17	Patent allowance	Positive	+5.1%	Japan patent allowance for liposomal Annamycin reconstitution methods strengthened IP.
Feb 13	Investor outreach initiative	Positive	+2.9%	Launch of CEO Corner platform to communicate strategy and clinical progress.

Pattern Detected

Recent news has generally seen price moves aligned with the nature of the event, with positive clinical/patent updates lifting shares and financing-related warrants triggering a sharp selloff.

Recent Company History

Over the past month, MBRX highlighted MIRACLE trial progress, including a 40% CRc rate and plans for unblinding after 45 patients, alongside confirmation of no cardiotoxicity in 90 subjects. A Japanese patent allowance further strengthened Annamycin IP, and the CEO Corner platform expanded investor communications. In contrast, a warrant exercise for about $8.3 million gross proceeds led to a steep decline, reflecting sensitivity to dilution versus operational milestones.

Regulatory & Risk Context

Active S-3 Shelf · $35.7 million

Shelf Active

Active S-3 Shelf Registration 2025-09-19

$35.7 million registered capacity

An effective-date-pending S-3 filed on 2025-09-19 registers up to 64,864,864 common shares for resale from Series F warrants. Moleculin receives cash only upon warrant exercise, which at full exercise could bring in $35.7 million gross, implying future dilution capacity alongside potential funding.

Market Pulse Summary

This announcement centers on Moleculin’s participation in a ROTH conference fireside chat, reinforci...

Analysis

This announcement centers on Moleculin’s participation in a ROTH conference fireside chat, reinforcing investor outreach rather than introducing new clinical or financial data. Within recent months, updates on the MIRACLE trial, Japanese patent protection, and proxy proposals around warrants and potential dilution have been more central catalysts. Investors may focus on how management frames these topics and the existing S-3 for 64,864,864 warrant shares during the event.

AI-generated analysis. Not financial advice.

– Management to participate in fireside chat presentation with Jonathan Aschoff, Senior Research Analyst at ROTH Capital Partners

HOUSTON, March 17, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it will participate in a fireside chat at the 38th Annual ROTH Conference being held March 22-24, 2026 in Dana Point, CA.

Details of the fireside chat presentation are as follows:

Date and Time: Tuesday, March 24, 2026 at 12:00-12:25 PM PT
Location: BROWN - HEALTHCARE - VIRTUAL (SUITE 1051)
Presenters: Walter Klemp, Founder, President, Chairman & CEO; Jon Foster, EVP & CFO
Registration Link: Here

Investors interested in arranging one-on-one meetings should contact their ROTH representative. For more information, please visit the conference website here.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as “Ara-C”) and, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications. 

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com

FAQ

When will Moleculin (MBRX) present at the ROTH Conference in March 2026?

Moleculin will present on March 24, 2026 at 12:00–12:25 PM PT. According to Moleculin, the company will participate in a fireside chat during the 38th Annual ROTH Conference in Dana Point, CA, with investor access via the conference platform.

Who will represent Moleculin (MBRX) in the March 24, 2026 fireside chat at ROTH?

Walter Klemp and Jon Foster will represent Moleculin in the fireside chat. According to Moleculin, Klemp will attend as Founder, President, Chairman & CEO and Foster as EVP & CFO for the presentation and investor Q&A during the session.

How can investors meet Moleculin (MBRX) at the 38th Annual ROTH Conference?

Investors can arrange one-on-one meetings through their ROTH representative. According to Moleculin, interested investors should contact their ROTH rep to request meetings and use the conference registration link to access scheduling and virtual suite details.

Is the Moleculin (MBRX) ROTH presentation available virtually on March 24, 2026?

Yes, the presentation is listed as virtual in the conference schedule. According to Moleculin, the fireside chat is in the BROWN - HEALTHCARE - VIRTUAL (SUITE 1051) slot, enabling remote attendance via the conference platform.

What topics will Moleculin (MBRX) cover in the March 24, 2026 fireside chat at ROTH?

The company will discuss recent developments and investor updates during the fireside chat. According to Moleculin, management will present in a moderated session with ROTH senior research analyst Jonathan Aschoff, followed by potential investor questions.

Where can I register to view Moleculin's (MBRX) ROTH Conference presentation on March 24, 2026?

Register via the ROTH conference website or the provided registration link. According to Moleculin, investors should use the conference registration link to access the virtual suite and see scheduling details for the March 24 fireside chat.